LIXTE Biotechnology Holdings (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy23/01/2026
Valar Labs Secures $22M to Transform AI-Driven Cancer DiagnosticsBy News Team03/06/2024 Valar Labs, a leader in AI-based medical diagnostics, has secured $22 million in Series A funding. This milestone will advance their groundbreaking technologies in cancer diagnosis.The…
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy23/01/2026
